Find Mirdametinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 391210-10-9, Pd0325901, Pd 0325901, Pd-0325901, Mirdametinib, (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
Molecular Formula
C16H14F3IN2O4
Molecular Weight
482.19  g/mol
InChI Key
SUDAHWBOROXANE-SECBINFHSA-N
FDA UNII
86K0J5AK6M

Mirdametinib
Mirdametinib is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.
1 2D Structure

Mirdametinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
2.1.2 InChI
InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
2.1.3 InChI Key
SUDAHWBOROXANE-SECBINFHSA-N
2.1.4 Canonical SMILES
C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O
2.1.5 Isomeric SMILES
C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O
2.2 Other Identifiers
2.2.1 UNII
86K0J5AK6M
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Mirdametinib

2. Pd 0325901

3. Pd 325901

4. Pd-0325901

5. Pd-325901

6. Pd0325901

7. Pd325901

2.3.2 Depositor-Supplied Synonyms

1. 391210-10-9

2. Pd0325901

3. Pd 0325901

4. Pd-0325901

5. Mirdametinib

6. (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide

7. Pd-325901

8. (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

9. Pd 325901

10. Mirdametinib [usan]

11. Pd325901

12. 86k0j5ak6m

13. Chembl507361

14. Chebi:88249

15. Pd 901

16. N-{[(2r)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide

17. Mirdametinib (usan)

18. Ncgc00189075-01

19. Pd 03525901

20. N-((r)-2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide

21. N-[((r)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide

22. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide

23. 391209-97-5

24. Unii-86k0j5ak6m

25. N-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide

26. 4bm

27. N-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide

28. N-((2r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-benzamide

29. Mirdametinib [inn]

30. Dsstox_cid_24024

31. Dsstox_rid_80100

32. Dsstox_gsid_44024

33. Mirdametinib [who-dd]

34. Pd0325901(mirdametinib)

35. Schembl172904

36. Gtpl7935

37. Dtxsid0044024

38. Ex-a102

39. Bcpp000126

40. Bdbm104963

41. Hms3648a14

42. Amy36437

43. Zinc3938683

44. Tox21_113364

45. Mfcd09909925

46. Nsc755770

47. Nsc800840

48. S1036

49. Who 11299

50. Akos015855518

51. Bcp9001057

52. Ccg-221316

53. Cs-0062

54. Db07101

55. Ex-8602

56. Nsc-755770

57. Nsc-800840

58. Ncgc00381744-09

59. Hy-10254

60. Us8575391, Q

61. Bb 0261791

62. Cas-391210-10-9

63. Sw218101-2

64. D11675

65. Pd-0325901,pd325901

66. Pd 0325901, >=98% (hplc)

67. Pd0325901 (pd325901)

68. Sr-01000946344

69. J-502503

70. Sr-01000946344-1

71. Brd-k49865102-001-01-9

72. Q27088255

73. Insolution Mek1/2 Inhibitor Iii, Pd0325901 - Cas 391210-10-9

74. Benzamide,n-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-

75. N-((r)-2,3-dihydroxy[propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide

76. N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

77. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- Benzamide

78. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2[(2-fluoro-4-iodophenyl)amino]-benzamide

79. (-)-n-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide

80. N-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide N-((2r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 482.19 g/mol
Molecular Formula C16H14F3IN2O4
XLogP33
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count7
Exact Mass481.99504 g/mol
Monoisotopic Mass481.99504 g/mol
Topological Polar Surface Area90.8 Ų
Heavy Atom Count26
Formal Charge0
Complexity465
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Mirdametinib Manufacturers

A Mirdametinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mirdametinib, including repackagers and relabelers. The FDA regulates Mirdametinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mirdametinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Mirdametinib Suppliers

A Mirdametinib supplier is an individual or a company that provides Mirdametinib active pharmaceutical ingredient (API) or Mirdametinib finished formulations upon request. The Mirdametinib suppliers may include Mirdametinib API manufacturers, exporters, distributors and traders.

Mirdametinib GMP

Mirdametinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Mirdametinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mirdametinib GMP manufacturer or Mirdametinib GMP API supplier for your needs.

Mirdametinib CoA

A Mirdametinib CoA (Certificate of Analysis) is a formal document that attests to Mirdametinib's compliance with Mirdametinib specifications and serves as a tool for batch-level quality control.

Mirdametinib CoA mostly includes findings from lab analyses of a specific batch. For each Mirdametinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Mirdametinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Mirdametinib EP), Mirdametinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mirdametinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty